drugset / Trial / NCT00826514

An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis

NCT00826514 ↗

Phase 2 Completed 62 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether tanezumab is effective in the treatment of pain associated with chronic prostatitis.

Timeline

Start
2009-03-25
Primary completion
2010-01-11
Completion
2010-03-17

Outcome

Missed primary endpoint

registry analysis (unspecified test); Tanezumab vs Placebo; Least squares mean difference -0.47 (95% CI -1.150 to 0.209) NCT00826514 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Tanezumab Monoclonal antibody 20 mg Intravenous

Indications